[HTML][HTML] The roles of matrix metalloproteinases and their inhibitors in human diseases
GA Cabral-Pacheco, I Garza-Veloz… - International journal of …, 2020 - mdpi.com
Matrix metalloproteinases (MMPs) are a family of zinc-dependent extracellular matrix (ECM)
remodeling endopeptidases that have the capacity to degrade almost every component of …
remodeling endopeptidases that have the capacity to degrade almost every component of …
The potential of serum neurofilament as biomarker for multiple sclerosis
Multiple sclerosis is a highly heterogeneous disease, and the detection of neuroaxonal
damage as well as its quantification is a critical step for patients. Blood-based serum …
damage as well as its quantification is a critical step for patients. Blood-based serum …
[HTML][HTML] Epstein–Barr virus in multiple sclerosis: theory and emerging immunotherapies
New treatments for multiple sclerosis (MS) focused on B cells have created an atmosphere
of excitement in the MS community. B cells are now known to play a major role in disease …
of excitement in the MS community. B cells are now known to play a major role in disease …
Ocrelizumab extended interval dosing in multiple sclerosis in times of COVID-19
L Rolfes, M Pawlitzki, S Pfeuffer, C Nelke… - Neurology …, 2021 - AAN Enterprises
Objective To evaluate the clinical consequences of extended interval dosing (EID) of
ocrelizumab in relapsing-remitting multiple sclerosis (RRMS) during the coronavirus disease …
ocrelizumab in relapsing-remitting multiple sclerosis (RRMS) during the coronavirus disease …
[HTML][HTML] Ocrelizumab Depletes CD20+ T Cells in Multiple Sclerosis Patients
S Gingele, TL Jacobus, FF Konen, MW Hümmert… - Cells, 2018 - mdpi.com
Ocrelizumab, a humanized monoclonal anti-CD20 antibody, has shown pronounced effects
in reduction of disease activity in multiple sclerosis (MS) patients and has recently been …
in reduction of disease activity in multiple sclerosis (MS) patients and has recently been …
Effect of ocrelizumab in blood leukocytes of patients with primary progressive MS
JI Fernández-Velasco, J Kuhle, E Monreal… - Neurology …, 2021 - AAN Enterprises
Objective To analyze the changes induced by ocrelizumab in blood immune cells of patients
with primary progressive MS (PPMS). Methods In this multicenter prospective study …
with primary progressive MS (PPMS). Methods In this multicenter prospective study …
Managing the side effects of multiple sclerosis therapy: pharmacotherapy options for patients
Introduction: Multiple sclerosis (MS) is an immune-mediated and neurodegenerative
disease with an unpredictable outcome. Immune-modulatory treatment aims at decreasing …
disease with an unpredictable outcome. Immune-modulatory treatment aims at decreasing …
[HTML][HTML] Safety of newer disease modifying therapies in multiple sclerosis
G Jalkh, R Abi Nahed, G Macaron, M Rensel - Vaccines, 2020 - mdpi.com
In the past decade, the therapeutic arsenal for multiple sclerosis has expanded greatly.
Newer more potent disease modifying therapies (DMTs) with varying mechanisms of actions …
Newer more potent disease modifying therapies (DMTs) with varying mechanisms of actions …
[HTML][HTML] The current standing of autologous haematopoietic stem cell transplantation for the treatment of multiple sclerosis
AG Willison, T Ruck, G Lenz, HP Hartung… - Journal of neurology, 2022 - Springer
Autologous haematopoietic stem cell transplantation (aHSCT) is gaining traction as a
valuable treatment option for patients affected by severe multiple sclerosis (MS), particularly …
valuable treatment option for patients affected by severe multiple sclerosis (MS), particularly …
Immune response to SARS-CoV-2 vaccination in relation to peripheral immune cell profiles among patients with multiple sclerosis receiving ocrelizumab
S Räuber, M Korsen, N Huntemann, L Rolfes… - Journal of Neurology …, 2022 - jnnp.bmj.com
Background Vaccination has proven to be effective in preventing SARS-CoV-2 transmission
and severe disease courses. However, immunocompromised patients have not been …
and severe disease courses. However, immunocompromised patients have not been …